Home › Compound Library › 1P-LSD (1-Propionyl-LSD)

1P-LSD (1-Propionyl-LSD)

Psychedelicoral · inferred

Semi-synthetic LSD prodrug with a propionyl group at the N1 position. Rapidly and nearly completely converted to LSD in vivo with ~100% bioavailability. 1P-LSD itself is only detectable for ~4h in serum after IV dosing — oral administration produces only LSD in plasma. Subjective effects indistinguishable from LSD. Sold as a "research chemical" in jurisdictions where LSD analogs are not explicitly scheduled.

Projected serum levels — 1 tabs (≈ 0.10 mg), as needed (shown daily)

1P-LSD (1-Propionyl-LSD) (precursor)LSD (Lysergic Acid Diethylamide)
1P-LSD (1-Propionyl-LSD) modeled serum levels, 1 tabs (≈ 0.10 mg) as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 tabs (≈ 0.10 mg) as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 0.022 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Psychedelic
Route modeled
Oral
Model confidence
inferred
Half-life
9.2 h
Common dose
1 tabs (≈ 0.10 mg)
Reference dose range
0.50–2 tabs (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • danger
    25I-NBOMe + 1P-LSD (1-Propionyl-LSD) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 25I-NBOMe both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + 1P-LSD (1-Propionyl-LSD) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 2C-I (2,5-Dimethoxy-4-iodophenethylamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + 1P-LSD (1-Propionyl-LSD) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 2C-B (4-Bromo-2,5-dimethoxyphenethylamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + 1P-LSD (1-Propionyl-LSD) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 3-MeO-PCP (3-Methoxyphencyclidine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + 1P-LSD (1-Propionyl-LSD) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 4-AcO-DMT (Psilacetin) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-HTP (5-Hydroxytryptophan) + 1P-LSD (1-Propionyl-LSD) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 5-HTP (5-Hydroxytryptophan) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 112 modeled interaction pairings for 1p-lsd (1-propionyl-lsd) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration Grumann C et al. · Drug Testing and Analysis, 2020 DOI

    Controlled human PK study showing 1P-LSD is completely converted to LSD after oral dosing (~100% bioavailability), with LSD terminal half-life of 6.4h and 1P-LSD detectable only transiently after IV administration.

1 published study referenced in the app, each with a plain-language summary.